All In Biotech

Investigational drug · Phase 2

selected combination of tinengotinib

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Prostate Cancer (CRPC).

Phase 2

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "selected combination of tinengotinib"

First trial start

2026

Sep 18, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "selected combination of tinengotinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Prostate Cancer (CRPC)

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "selected combination of tinengotinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Prostate Cancer (CRPC)

  • tinengotinibTT-00420Phase 36 trials

    TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)

  • TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.